All In Biotech

Drug Trial Radar · NCT01207011

Amrubicin (AMR) Trial in Patients With Non-small Cell Lung Cancer

A Randomised, Open-Label Phase 3 Trial Comparing Amrubicin Versus Docetaxel in Patients With Non-Small Cell Lung Cancer After Failure of First-Line Chemotherapy

Last checked: Nov 19, 2026Latest source record: Apr 12, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 202 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

202

Actual

Start

Oct 2010

Primary completion

Jun 2014

Study completion Jun 2014

Sponsor

Lead sponsor
Sumitomo Pharma Co., Ltd.Industry
Sponsor type
Industry
First posted
Sep 22, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 20 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is to evaluate the effect of amrubicin (AMR) compared to docetaxel (DOC) in the treatment of non-small cell lung cancer (NSCLC).

Conditions

  • Lung Cancer

Interventions

  • Amrubicin hydroclorideDrug

    AMR was administered i.v. by 35mg/m2 at day 1, 2 and 3 followed by 3 week rest as 1 course.

  • DocetaxelDrug

    DOC was administered i.v. by 60mg/m2 at day 1 followed by 3 week rest as 1 course.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survivalTime frame: 3.3 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • 32 Sites

    Multiple Locations, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.